Advertisement
Advertisement
U.S. markets open in 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Mucinno Holding, Inc. (MCNO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0267-0.0003 (-1.11%)
At close: 03:38PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0270
Open0.0311
BidN/A x N/A
AskN/A x N/A
Day's Range0.0267 - 0.0360
52 Week Range0.0201 - 0.6650
Volume55,030
Avg. Volume119,456
Market Cap95,623
Beta (5Y Monthly)-1.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MCNO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MUCINNO HOLDING INC
    Analyst Report: Incyte Corp.Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Iclusig, Pemazyre, and Olumiant. Jakafi treats polycythemia vera (PV), a type of blood cancer; myelofibrosis (MF), a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease (GVHD), while Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer, and has several active Phase 2 and 3 programs in oncology.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
Advertisement
Advertisement